Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NHL)

Next Previous
Trial Profile

A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NHL)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WTX-330 (Primary)
  • Indications Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Werewolf Therapeutics

Most Recent Events

  • 10 Feb 2026 Status changed from recruiting to active, no longer recruiting.
  • 18 Dec 2025 Results (as of October 31, 2025) presented in the Werewolf Therapeutics Media Release
  • 18 Dec 2025 According to a Werewolf Therapeutics media release, additional data expected in the first half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top